Is AUPH research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AUPH. It does not provide personalized investment advice.

AUPH (Aurinia Pharmaceuticals Inc) Stock Analysis - Financials

Aurinia Pharmaceuticals Inc (AUPH) is a publicly traded Healthcare sector company. As of July 6, 2026, AUPH trades at $15.87 with a market cap of $2.01B and a P/E ratio of 6.91. AUPH moved +1.63% today. Year to date, AUPH is -1.33%; over the trailing twelve months it is +108.41%. Its 52-week range spans $6.55 to $19.25. Analyst consensus is buy with an average price target of $15.67. Rallies surfaces AUPH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are AUPH's key financials?

AUPH financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. AUPH recently traded at $15.87. Market cap is $2.01B. P/E ratio is 6.91. Revenue is $298.30M.

AUPH Key Metrics

Key financial metrics for AUPH
Metric	Value
Price	$15.87
Market Cap	$2.01B
P/E Ratio	6.91
EPS	$2.26
Dividend Yield	0.00%
52-Week High	$19.25
52-Week Low	$6.55
Volume	353.48K
Avg Volume	0
Revenue (TTM)	$298.30M
Net Income	$298.21M
Gross Margin	89.74%

AUPH Analyst Consensus

3 analysts cover AUPH: 0 strong buy, 1 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.67.

Common questions about AUPH

What are AUPH's key financials?: AUPH financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. AUPH recently traded at $15.87. Market cap is $2.01B. P/E ratio is 6.91. Revenue is $298.30M.
Is AUPH research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AUPH. It does not provide personalized investment advice.